EPAS1 and renal carcinoma: A specific small molecule inhibitor of HIF2α has been recently approved for von‐Hippel Lindau disease and is being tested for renal cancer and glioblastoma (Wallace et al, 2016; Courtney et al, 2018; Renfrow et al, 2018; Hasanov & Jonasch, 2021).